What if we could treat hearing loss before it shows up on a standard audiogram? Celia Belline, CEO and co-founder of Cilcare, shares progress on the company’s lead compound, CIL001, developed to treat cochlear synaptopathy—often referred to as hidden hearing loss.

A Phase 2A clinical trial is planned to begin later this year, targeting individuals with type 2 diabetes who are more likely to present early signs of the condition.The conversation explores how early-stage auditory synaptic damage may contribute to both hearing difficulties in noise and tinnitus, why timely intervention matters, and what’s ahead for the hearing therapeutics field.🔗 Learn more: https://www.cilcare.comBe sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X.- https://x.com/WeekinHearing- https://www.instagram.com/thisweekinhearing/- https://www.linkedin.com/company/this-week-in-hearing- https://hearinghealthmatters.org/thisweek/